Cargando…

Study on the mechanism of Shenkang injection in the treatment of chronic renal failure based on the strategy of "Network pharmacology—Molecular docking—Key target validation"

OBJECTIVE: To explore the potential mechanism of Shenkang injection (SKI) in the treatment of chronic renal failure based on network pharmacology and molecular docking technology, and to verify the core targets and key pathways by using the renal failure model. METHODS: The active components and tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Lin, Wang, Xiaohui, Sun, Zhi, Bao, Xiaoyue, Xue, Lianping, Xu, Zhanmei, Dong, Pengfei, Xia, Jinlan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553805/
https://www.ncbi.nlm.nih.gov/pubmed/37796994
http://dx.doi.org/10.1371/journal.pone.0291621
_version_ 1785116261027414016
author Zhou, Lin
Wang, Xiaohui
Sun, Zhi
Bao, Xiaoyue
Xue, Lianping
Xu, Zhanmei
Dong, Pengfei
Xia, Jinlan
author_facet Zhou, Lin
Wang, Xiaohui
Sun, Zhi
Bao, Xiaoyue
Xue, Lianping
Xu, Zhanmei
Dong, Pengfei
Xia, Jinlan
author_sort Zhou, Lin
collection PubMed
description OBJECTIVE: To explore the potential mechanism of Shenkang injection (SKI) in the treatment of chronic renal failure based on network pharmacology and molecular docking technology, and to verify the core targets and key pathways by using the renal failure model. METHODS: The active components and targets of Shenkang injection were retrieved by TCMSP database, and the disease related targets were obtained by OMIM, GeneCards and other databases. Then, the intersection was obtained, and were imported into String database for PPI analysis. After further screening of core targets, GO and KEGG analysis were performed. Autodock software was used to predict the molecular docking and binding ability of the selected active ingredients and core targets. Chronic renal failure (CRF) model was established by adenine induction in rats, and the pathological observation of renal tissues was conducted. Meanwhile, the effects of Shenkang injection and its active components on core targets and pathways of renal tissues were verified. RESULTS: The results of network pharmacology showed that the main components of Shenkang injection might be hydroxysafflor yellow A (HSYA)、tanshinol、rheum emodin、Astragaloside IV. Through enrichment analysis of core targets, it was found that Shenkang injection may play an anti-chronic renal failure effect through PI3K-Akt signaling pathway. Molecular docking results showed that the above pharmacodynamic components had strong binding ability with the target proteins PI3K and Akt. The results of animal experiments showed that renal function indexes of Shenkang injection group and pharmacodynamic component group were significantly improved compared with model group. HE staining results showed that the pathological status of the kidney was significantly improved in SKI and pharmacodynamic component treatment groups. Immunohistochemical results showed that the renal fibrosis status was significantly reduced in SKI and pharmacodynamic component treatment groups. q-RTPCR and WB results showed that the expression levels of PI3K and Akt were significantly decreased in the treatment groups (P< 0.05). CONCLUSIONS: Shenkang injection may inhibit PI3K-Akt signaling pathway to play an anti-chronic renal failure role through the pharmacodynamic component hydroxysafflor yellow A (HSYA), tanshinol, rheum emodin, Astragaloside IV.
format Online
Article
Text
id pubmed-10553805
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-105538052023-10-06 Study on the mechanism of Shenkang injection in the treatment of chronic renal failure based on the strategy of "Network pharmacology—Molecular docking—Key target validation" Zhou, Lin Wang, Xiaohui Sun, Zhi Bao, Xiaoyue Xue, Lianping Xu, Zhanmei Dong, Pengfei Xia, Jinlan PLoS One Research Article OBJECTIVE: To explore the potential mechanism of Shenkang injection (SKI) in the treatment of chronic renal failure based on network pharmacology and molecular docking technology, and to verify the core targets and key pathways by using the renal failure model. METHODS: The active components and targets of Shenkang injection were retrieved by TCMSP database, and the disease related targets were obtained by OMIM, GeneCards and other databases. Then, the intersection was obtained, and were imported into String database for PPI analysis. After further screening of core targets, GO and KEGG analysis were performed. Autodock software was used to predict the molecular docking and binding ability of the selected active ingredients and core targets. Chronic renal failure (CRF) model was established by adenine induction in rats, and the pathological observation of renal tissues was conducted. Meanwhile, the effects of Shenkang injection and its active components on core targets and pathways of renal tissues were verified. RESULTS: The results of network pharmacology showed that the main components of Shenkang injection might be hydroxysafflor yellow A (HSYA)、tanshinol、rheum emodin、Astragaloside IV. Through enrichment analysis of core targets, it was found that Shenkang injection may play an anti-chronic renal failure effect through PI3K-Akt signaling pathway. Molecular docking results showed that the above pharmacodynamic components had strong binding ability with the target proteins PI3K and Akt. The results of animal experiments showed that renal function indexes of Shenkang injection group and pharmacodynamic component group were significantly improved compared with model group. HE staining results showed that the pathological status of the kidney was significantly improved in SKI and pharmacodynamic component treatment groups. Immunohistochemical results showed that the renal fibrosis status was significantly reduced in SKI and pharmacodynamic component treatment groups. q-RTPCR and WB results showed that the expression levels of PI3K and Akt were significantly decreased in the treatment groups (P< 0.05). CONCLUSIONS: Shenkang injection may inhibit PI3K-Akt signaling pathway to play an anti-chronic renal failure role through the pharmacodynamic component hydroxysafflor yellow A (HSYA), tanshinol, rheum emodin, Astragaloside IV. Public Library of Science 2023-10-05 /pmc/articles/PMC10553805/ /pubmed/37796994 http://dx.doi.org/10.1371/journal.pone.0291621 Text en © 2023 Zhou et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Zhou, Lin
Wang, Xiaohui
Sun, Zhi
Bao, Xiaoyue
Xue, Lianping
Xu, Zhanmei
Dong, Pengfei
Xia, Jinlan
Study on the mechanism of Shenkang injection in the treatment of chronic renal failure based on the strategy of "Network pharmacology—Molecular docking—Key target validation"
title Study on the mechanism of Shenkang injection in the treatment of chronic renal failure based on the strategy of "Network pharmacology—Molecular docking—Key target validation"
title_full Study on the mechanism of Shenkang injection in the treatment of chronic renal failure based on the strategy of "Network pharmacology—Molecular docking—Key target validation"
title_fullStr Study on the mechanism of Shenkang injection in the treatment of chronic renal failure based on the strategy of "Network pharmacology—Molecular docking—Key target validation"
title_full_unstemmed Study on the mechanism of Shenkang injection in the treatment of chronic renal failure based on the strategy of "Network pharmacology—Molecular docking—Key target validation"
title_short Study on the mechanism of Shenkang injection in the treatment of chronic renal failure based on the strategy of "Network pharmacology—Molecular docking—Key target validation"
title_sort study on the mechanism of shenkang injection in the treatment of chronic renal failure based on the strategy of "network pharmacology—molecular docking—key target validation"
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553805/
https://www.ncbi.nlm.nih.gov/pubmed/37796994
http://dx.doi.org/10.1371/journal.pone.0291621
work_keys_str_mv AT zhoulin studyonthemechanismofshenkanginjectioninthetreatmentofchronicrenalfailurebasedonthestrategyofnetworkpharmacologymoleculardockingkeytargetvalidation
AT wangxiaohui studyonthemechanismofshenkanginjectioninthetreatmentofchronicrenalfailurebasedonthestrategyofnetworkpharmacologymoleculardockingkeytargetvalidation
AT sunzhi studyonthemechanismofshenkanginjectioninthetreatmentofchronicrenalfailurebasedonthestrategyofnetworkpharmacologymoleculardockingkeytargetvalidation
AT baoxiaoyue studyonthemechanismofshenkanginjectioninthetreatmentofchronicrenalfailurebasedonthestrategyofnetworkpharmacologymoleculardockingkeytargetvalidation
AT xuelianping studyonthemechanismofshenkanginjectioninthetreatmentofchronicrenalfailurebasedonthestrategyofnetworkpharmacologymoleculardockingkeytargetvalidation
AT xuzhanmei studyonthemechanismofshenkanginjectioninthetreatmentofchronicrenalfailurebasedonthestrategyofnetworkpharmacologymoleculardockingkeytargetvalidation
AT dongpengfei studyonthemechanismofshenkanginjectioninthetreatmentofchronicrenalfailurebasedonthestrategyofnetworkpharmacologymoleculardockingkeytargetvalidation
AT xiajinlan studyonthemechanismofshenkanginjectioninthetreatmentofchronicrenalfailurebasedonthestrategyofnetworkpharmacologymoleculardockingkeytargetvalidation